Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2013

Galena Buys Orexo’s Pain Drug for $10M+

  • Orexo sold Abstral® (fentanyl) sublingual tablets to Galena Biopharma. Under the agreement, Galena will pay Orexo $10 million up front and an additional $5 million within the first 12 months after signing, plus low double-digit royalties and milestone payments based on prespecified sales levels.

    Abstral is a sublingual rapid acting formulation of fentanyl, an opioid, and is indicated for the management of breakthrough pain. It was approved by the FDA in 2011. In June 2012, Orexo acquired all U.S. rights to Abstral from ProStrakan Group as a part of a reconfiguration of the worldwide rights to Abstral. With completion of the current transaction, Orexo has secured net cash payments of over SEK 700 million ($110 million) and in addition milestones and royalty payments.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »